Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Aug 1;188(3):365-9.
doi: 10.1164/rccm.201209-1640OC.

Causes and circumstances of death in pulmonary arterial hypertension

Adriano R Tonelli  1 , Vineesha Arelli, Omar A Minai, Jennie Newman, Nancy Bair, Gustavo A Heresi, Raed A Dweik
Affiliations
Comparative Study

Causes and circumstances of death in pulmonary arterial hypertension

Adriano R Tonelli et al. Am J Respir Crit Care Med. .

Abstract

Rationale: The causes and circumstances surrounding death are understudied in patients with pulmonary arterial hypertension (PAH).

Objectives: We sought to determine the specific reasons and characteristics surrounding the death of patients with PAH.

Methods: All deaths of patients with pulmonary hypertension (PH) followed in the Cleveland Clinic Pulmonary Vascular Program were prospectively reviewed by the PH team. A total of 84 patients with PAH (age 58 ± 14 yr; 73% females) who died between June 2008 and May 2012 were included.

Measurements and main results: PH was determined to be the direct cause of death (right heart failure or sudden death) in 37 (44%) patients; PH contributed to but did not directly cause death in 37 (44%) patients; and the death was not related to PH in the remaining cases (n = 7; 8.3%). In three (3.6%) patients the final cause of death could not be adequately assessed. Most patients died in a healthcare environment and most received PH-specific therapies. In our cohort, 50% of all patients with PAH and 75.7% of those who died of right heart failure received parenteral prostanoid therapy. Less than half of patients had advanced healthcare directives.

Conclusions: Most patients with PAH in our cohort died of their disease; however, right ventricular failure or sudden death was the sole cause of death in less than half of patients.

PubMed Disclaimer

Figures

<i>Figure 1.</i>
Figure 1.
Patient inclusion flow chart. PH = pulmonary hypertension.
<i>Figure 2.</i>
Figure 2.
Treatments provided to patients with pulmonary arterial hypertension (PAH) that died of worsening pulmonary hypertension (PH). *Number of patients is 81 because we excluded three patients with undetermined cause of death. All these patients received PH-specific therapies. Comorbidities include renal failure; cirrhosis; schizophrenia; coronary artery disease; bacteremia; and chronic gastrointestinal bleeding (arteriovenous malformation). Values are presented as n (%). ILD = interstitial lung disease; IV = intravenous; NYHA = New York Heart Association; P = patients; SQ = subcutaneous; Tx = treatment.
See this image and copyright information in PMC

Comment in

References

    1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association. Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250–2294. - PubMed
    1. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, McGoon M, Naeije R, Olschewski H, Oudiz RJ, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:S55–S66. - PubMed
    1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54:S43–S54. - PubMed
    1. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485–491. - PubMed
    1. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL) Circulation. 2010;122:164–172. - PubMed

Publication types